GSK3β identified as a driver of drug resistance in BRAF mutant melanoma

Download PDF Copy Reviewed OncotargetApr 11 2025A new research perspective was published inOncotarget,Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells."In this work, first author Diana Crisan and corresponding author Abhijit Basu from theUniversity Hospital Ulmled a team that presents experimental evidence pointing to the protein GSK3β as a key contributor to drug resistance in melanoma. Their findings suggest that GSK3β becomes increasingly active in cancer cells during treatment, helping them survive and adapt despite ongoing therapy with BRAF inhibitors.Melanoma is a type of skin cancer in which nearly half of patients have mutations in the BRAF gene that accelerate tumor growth. While treatments targeting BRAF, known as BRAF inhibitors, initially work well, tumors often find ways to fight back. This research perspective explores how GSK3β, a protein involved in metabolism and cell survival, becomes m...